Articles related to BLADDER CANCER

This study illuminates the potential of preoperative circulating tumor DNA to redefine the approach to treating high-risk upper tract urothelial carcinoma, offering a nuanced tool for assessing the necessity of neoadjuvant chemotherapy and tailoring patient care.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.

The future of advanced bladder cancer treatment has been crystallized by the findings of the EV302 study, which demonstrated a median overall survival of 31.5 months with enfortumab vedotin-ejfv plus pembrolizumab.

The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.

Explore the nuanced implications of the FDA’s accelerated approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible urothelial carcinoma patients, including questions on optimal treatment duration and adverse effects.